NICE approves three quarters of CDF group 1 drugs for routine use

17 November 2016 - More than 75% of treatments in the Cancer Drugs Fund which have been looked at again by ...

Read more →

Did it matter that the Cancer Drugs Fund was not NICE? A retrospective review

3 October 2016 - This article reviews the means by which the Cancer Drugs Fund made recent funding decisions for cancer ...

Read more →

Rare cancer drug which significantly delays progression of advanced thyroid cancer is left off relaunched Cancer Drugs Fund

2 August 2016 - People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima (lenvatinib mesylate) is not scheduled for ...

Read more →

Japan's Eisai weighs legal action in UK cancer drug row

8 July 2016 - Japan's Eisai said on Friday it would consider all options, including possible legal action, to fight delays ...

Read more →

At last, NICE to take over the Cancer Drugs Fund

7 March 2016 - The reincarnation of the Cancer Drugs Fund will benefit both NICE and the NHS. ...

Read more →

New “managed access” process for Cancer Drugs Fund to go ahead, NHS England confirms

29 February 2016 - NHS England has confirmed that from 1 July its Cancer Drugs Fund will operate on a “managed ...

Read more →

ABPI comments on the NHS England's decision for the Cancer Drugs Fund

26 February 2016 - The ABPI is disappointed by today's decision by NHS England that it will continue to push ahead ...

Read more →

NHS plan to reassess value of cancer drugs alarms patient groups

26 February 2016 - NHS England backs tighter control on drugs spending, which opponents say would set treatment ‘back by a ...

Read more →